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Epidemiological research into SARS- CoV-2 is 
challenging. A combination of regional differ-
ences, variations in symptoms among infected 
people and a limited (but increasing) capacity 
to undertake swab testing and focused screen-
ing in groups such as carers in nursing homes, 
has made it difficult to understand the true 
prevalence of infection. Clear insights into 
many questions have been slow to emerge; for 
example, the factors that are associated with 
being infected with SARS- CoV-2 as opposed 
to dying of COVID-19, which is sadly easier to 
measure. Large, population-representative 
cohorts with detailed demographic and health 
information sampled by experienced tech-
nicians at multiple time points are needed. 
Some studies, such as the UK REACT study1 
and ENE- COVID in Spain2, go a long way to 
meeting these requirements, but all have limi-
tations. Antibody testing offers a different 
insight — evidence of previous infection with 
SARS- CoV-2. Well- designed seroprevalence 
studies are critical to determine the propor-
tion of a population who have been infected 
to help predict future infection dynamics and 
guide public health policy.
A new study uses a pragmatic approach 
to define the prevalence of previous infec-
tion by testing for antibodies to SARS- CoV-2 
in routinely collected blood from randomly 
sampled patients on haemodialysis across 
the USA3. These patients already undergo 
blood tests every month to assess dialysis 
systematically sampled, of whom >28,000 were 
tested in July 2020. The age and sex distri-
butions of the sampled population were fairly 
similar to the US adult dialysis population 
although patients from the West were over-
represented and those from the Midwest 
were under represented. Race and ethnicity 
was unknown in 40% of patients; as a proxy, 
patient- level residence data was linked to 
ZIP- code tabulation area (ZCTA) data from 
the 2018 American Community Survey to 
identify each patient’s majority neighbourhood 
race and ethnicity.
The study reports that 8.0% of tested 
patients were seropositive for SARS-CoV-2 
anti bodies (Table 1). Using ZCTA data, the 
adjusted risk of seropositivity was high est 
among non- Hispanic Black and Hispanic and 
Black patients and was lowest among non- 
Hispanic white patients. The risk was also 
increased by poverty and living in densely 
populated and urbanized areas. These find-
ings are consistent with the results of inter-
national research in the general population. 
When standardized to the US adult popu-
lation using weighted stratification by census 
region, age and sex, seropositivity was esti-
mated to be 9.3%. This estimate suggests that 
over 90% of the US adult population could be 
susceptible to SARS- CoV-2, which is alarm-
ing considering the scale of impact on the 
country so far but is consistent with findings 
from England1 and Spain2.
In addition, the research identified striking 
variation in seroprevalence, ranging from 0% 
in seven states to 34% in New York state, con-
sistent with the substantial outbreak in the city4. 
State seroprevalence correlated with cumulative 
deaths and cases per 100,000 popu lation and 
the odds of seroposi tivity were lower in areas 
where workplace visits were reduced before 
nationwide restrictions were implemented. 
These findings offer the tantalizing prospect of 
using seroprevalence to provide feedback on 
policy changes but equally might result from 
an ecological fallacy. For example, patients on 
haemodialy sis might have undertaken strict 
shielding measures to protect themselves if 
adequacy and management of kidney failure 
complications, so their blood can be tested 
for SARS- CoV-2 antibodies without addi-
tional venepuncture. This approach mitigates 
bias through non- response that would be 
expected for studies requiring blood testing 
in the general population. In addition, dialysis 
centres are incentivized to undertake routine 
monthly blood testing, ensuring very high 
data completeness. The study was funded by 
Ascend Clinical, a commercial laboratory that 
processed the tests using a high- sensitivity, 
high- specificity chemiluminescence assay. 
The laboratory receives specimens from 
approximately 63,000 patients in around 1,300 
dialysis facilities; this cohort comprised the 
source population.
As the patients on dialysis were older and 
more likely to be Black than the US general 
adult population, the researchers standard-
ized their seroprevalence estimates to this 
population. They then correlated their results 
with publicly available state-level population 
measures of cases, deaths and testing, as well as 
county-level measures in California, New York 
and Texas, which had the highest densities of 
participants. More than 31,000 patients were 
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they lived in regions with rapidly rising infec-
tion rates, which also triggered policy changes 
such as a reduction in workplace visits.
The idea of conducting nationwide serolog-
ical surveillance through a randomly sampled 
sentinel population of patients on haemodi-
alysis is an attractive proposition. However, 
concerns exist about whether conclusions for 
the general population can be reliably derived 
from the haemodialysis popu lation even when 
standardization methods are used. Patients on 
dialysis are subject to increased risk of infec-
tion due to three times weekly visits to haemo-
dialysis facilities, which often involve the use of 
shared patient transport and close contact with 
other patients despite infection control meas-
ures. In addition, patients with kidney failure 
often have high levels of comorbidity and 
frailty, leading to increased risk of transmis-
sion through contact with carers. Outbreaks 
of COVID-19 within haemodialysis units have 
been reported worldwide5.
On the other hand, seroprevalence in 
the general population could potentially be 
underestimated using data from patients on 
dialysis. Mortality from COVID-19 among 
patients on haemodialysis is higher than in the 
general population, resulting in survivor bias. 
The latest report from the UK Renal registry, 
which includes data from >2,700 patients on 
haemodialysis with COVID-19, reported a 
mortality of 22%6, which is remarkably con-
sistent with reports from other countries5. In 
addition, patients on dialysis are likely to take 
greater precautions with physical distancing 
measures than the general population due to 
their increased risk, so may be at lower risk 
of community transmission. Lastly, patients 
on haemodialy sis generate a weaker immune 
response to stimuli such as the Hepatitis B 
vaccine7 and so may be less likely to seroconvert 
than the general population. Although a recent 
study demonstrated 97% seroconversion in 
patients with kidney failure and previously con-
firmed SARS- CoV-2 infection8, similar to rates 
seen in the general population9, the compara-
tive proportion who seroconvert after asymp-
tomatic infection remains unknown. Before a 
strategy of serological surveillance of patients 
on haemodialysis could be adopted to guide 
wider public health policy, longitudinal anti-
gen screening studies would be needed to better 
understand asymptomatic seroconversion in 
these patients. In addition, practical difficulties 
exist. The rapid results and information flow as 
well as the likely consistency of testing meth-
ods in the current study were achieved because 
the antibodies were measured at a central lab-
oratory specializing in blood tests for patients 
with kidney failure; these advantages would not 
translate to blood samples being measured at 
local hospital laboratories in countries such as 
the UK.
This research shows the huge potential 
of monitoring infectious disease prevalence 
in dialysis populations but given the inten-
sity of interest in SARS- CoV-2 seropreva-
lence for policymaking and public health 
messag ing, little room exists for speculation. 
The clinical utility of serological surveillance 
for SARS- CoV-2 in patients on haemodialy-
sis is uncertain and the duration of anti-
body response as well as the extent to which 
humoral and cellular processes confer pro-
tection from reinfection remain unknown 
with recent reports of waning seroprevalence 
over time10. However, at the very least, sur-
veillance provides invaluable information 
on asymptomatic cases of SARS- CoV-2 
infection in patients on haemodialysis to 
better understand local outbreaks and guide 
improvements for infection prevention in this 
extremely vulnerable patient group.
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for US adult population 
(n = 253,815,197)
Hispanic 9.0 (8.2–10.0) 9.4 (8.5–10.3) 11.3 (9.8–12.9)
Hispanic and Black 14.6 (13.3–16.1) 14.5 (13.2–15.9) 16.3 (14.3–18.5)
Non- Hispanic Black 14.7 (13.3–16.3) 14.1 (12.9–15.5) 13.9 (12.1–16.0)
Non- Hispanic white 4.2 (3.8–4.7) 4.3 (3.8–4.7) 4.8 (4.1–5.5)
Other 7.3 (6.8–7.9) 8.0 (7.4–8.6) 8.9 (8.0–9.8)
Overall 8·0 (7·7–8·4) 8·3 (8·0–8·6) 9·3 (8·8–9·9)
ZCTA, ZIP- code tabulation area. Data obtained from ref.3.
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